Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention

by Felipe V. Gomes, Anthony A. Grace
Published 2021-04-01

Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia

by Susan F. Sonnenschein, Felipe V. Gomes, Anthony A. Grace
Published 2020-06-01

Are CB2 Receptors a New Target for Schizophrenia Treatment?

by Isadora L. Cortez, Naielly Rodrigues da Silva, Francisco S. Guimarães, Felipe V. Gomes
Published 2020-10-01

Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders

by Alline C. Campos, Manoela V. Fogaça, Franciele F. Scarante, Sâmia R. L. Joca, Amanda J. Sales, Felipe V. Gomes, Andreza B. Sonego, Naielly S. Rodrigues, Ismael Galve-Roperh, Ismael Galve-Roperh, Francisco S. Guimarães
Published 2017-05-01

Correction: Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.

by Aviva Breuer, Christeene G Haj, Manoela V Fogaça, Felipe V Gomes, Nicole Rodrigues Silva, João Francisco Pedrazzi, Elaine A Del Bel, Jaime C Hallak, José A Crippa, Antonio W Zuardi, Raphael Mechoulam, Francisco S Guimarães
Published 2016-01-01

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.

by Aviva Breuer, Christeene G Haj, Manoela V Fogaça, Felipe V Gomes, Nicole Rodrigues Silva, João Francisco Pedrazzi, Elaine A Del Bel, Elaine A Del Bel, Jaime C Hallak, José A Crippa, Antonio W Zuardi, Raphael Mechoulam, Francisco S Guimarães
Published 2016-01-01